Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The last earnings update was 77 days ago. More info.
Add to Portfolio Compare Print
- Corbus Pharmaceuticals Holdings has significant price volatility in the past 3 months.
CRBP Share Price and Events
7 Day Returns
1 Year Returns
CRBP Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings (CRBP) | -2.9% | 40.3% | 9% | -17.1% | 467.7% | - |
| US Biotechs | -0.5% | 19.3% | 5.8% | -8.4% | 8.9% | 15.3% |
| US Market | 0.7% | 10.2% | -1% | -8.1% | 38.8% | 38.9% |
1 Year Return vs Industry and Market
- CRBP underperformed the Biotechs industry which returned -8.4% over the past year.
- CRBP underperformed the Market in United States of America which returned -8.1% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Corbus Pharmaceuticals Holdings
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Corbus Pharmaceuticals Holdings.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 12.2% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 7.3% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.31 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.306 (1 + (1- 21%) (0%)) |
1.306 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.31 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.306 * 7.27%) |
12.22% |
Discounted Cash Flow Calculation for NasdaqGM:CRBP using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Corbus Pharmaceuticals Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (USD, Millions) | -60.74 | -79.42 | -73.59 | 35.16 | 235.67 |
| Source | Analyst x3 | Analyst x3 | Analyst x3 | Analyst x3 | Analyst x3 |
|
Present Value Discounted (@ 12.22%) |
-54.12 | -63.06 | -52.07 | 22.16 | 132.39 |
| Present value of next 5 years cash flows | $-14.69 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= $235.67 × (1 + 2.73%) ÷ (12.22% – 2.73%) |
$2,549.93 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= $2,549.93 ÷ (1 + 12.22%)5 |
$1,432.48 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= $-14.69 + $1,432.48 |
$1,417.79 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $1,417.79 / 57.24 |
$24.77 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $24.77 |
| Current discount | Discount to share price of
$7.38
= -1 x ($7.38 - $24.77) / $24.77 |
70.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Corbus Pharmaceuticals Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Corbus Pharmaceuticals Holdings's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Corbus Pharmaceuticals Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Corbus Pharmaceuticals Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in USD | $-0.87 |
| NasdaqGM:CRBP Share Price ** | NasdaqGM (2019-01-23) in USD | $7.38 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 32 Publicly-Listed Biotechs Companies | 26.07x |
| United States of America Market PE Ratio | Median Figure of 3,026 Publicly-Listed Companies | 16.96x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Corbus Pharmaceuticals Holdings.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:CRBP Share Price ÷ EPS (both in USD) = 7.38 ÷ -0.87 |
-8.45x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Corbus Pharmaceuticals Holdings is loss making, we can't compare its value to the US Biotechs industry average.
- Corbus Pharmaceuticals Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Corbus Pharmaceuticals Holdings's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -8.45x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
47.6%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 25 Publicly-Listed Biotechs Companies | 2.35x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.26x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Corbus Pharmaceuticals Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Corbus Pharmaceuticals Holdings's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in USD | $0.75 |
| NasdaqGM:CRBP Share Price * | NasdaqGM (2019-01-23) in USD | $7.38 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 400 Publicly-Listed Biotechs Companies | 2.89x |
| United States of America Market PB Ratio | Median Figure of 5,102 Publicly-Listed Companies | 1.75x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:CRBP Share Price ÷ Book Value per Share (both in USD) = 7.38 ÷ 0.75 |
9.85x |
* Primary Listing of Corbus Pharmaceuticals Holdings.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Corbus Pharmaceuticals Holdings is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Corbus Pharmaceuticals Holdings's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Corbus Pharmaceuticals Holdings has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the United States of America market average.
- Corbus Pharmaceuticals Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:CRBP Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 47.6% |
| NasdaqGM:CRBP Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 78.1% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 21.9% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 15.2% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.6% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 448 | 299 | 148 | 6 |
| 2022-12-31 | 186 | 69 | 46 | 6 |
| 2021-12-31 | 34 | -70 | -87 | 6 |
| 2020-12-31 | 8 | -73 | -72 | 6 |
| 2019-12-31 | 7 | -52 | -54 | 5 |
| 2018-12-31 | 4 | -45 | -52 | 6 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 3 | -25 | -49 |
| 2018-06-30 | 3 | -23 | -41 |
| 2018-03-31 | 2 | -23 | -37 |
| 2017-12-31 | 2 | -28 | -32 |
| 2017-09-30 | 3 | -24 | -29 |
| 2017-06-30 | 3 | -21 | -28 |
| 2017-03-31 | 3 | -18 | -25 |
| 2016-12-31 | 2 | -14 | -20 |
| 2016-09-30 | 2 | -9 | -15 |
| 2016-06-30 | 1 | -8 | -12 |
| 2016-03-31 | 1 | -6 | -10 |
| 2015-12-31 | 1 | -5 | -9 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 3.21 | 6.79 | 1.17 | 5.00 |
| 2022-12-31 | 0.72 | 2.71 | -0.32 | 5.00 |
| 2021-12-31 | -1.35 | -1.17 | -1.50 | 4.00 |
| 2020-12-31 | -1.14 | -0.87 | -1.43 | 5.00 |
| 2019-12-31 | -0.95 | -0.53 | -1.28 | 7.00 |
| 2018-12-31 | -0.93 | -0.88 | -0.97 | 5.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-09-30 | -0.87 |
| 2018-06-30 | -0.76 |
| 2018-03-31 | -0.70 |
| 2017-12-31 | -0.65 |
| 2017-09-30 | -0.61 |
| 2017-06-30 | -0.60 |
| 2017-03-31 | -0.57 |
| 2016-12-31 | -0.49 |
| 2016-09-30 | -0.38 |
| 2016-06-30 | -0.32 |
| 2016-03-31 | -0.30 |
| 2015-12-31 | -0.28 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Corbus Pharmaceuticals Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Corbus Pharmaceuticals Holdings's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Corbus Pharmaceuticals Holdings has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Corbus Pharmaceuticals Holdings performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Corbus Pharmaceuticals Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Corbus Pharmaceuticals Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Corbus Pharmaceuticals Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 2.89 | -49.06 | 11.79 | |
| 2018-06-30 | 2.60 | -41.42 | 10.74 | |
| 2018-03-31 | 2.10 | -36.65 | 9.63 | |
| 2017-12-31 | 2.44 | -32.42 | 8.96 | |
| 2017-09-30 | 2.82 | -29.30 | 8.96 | |
| 2017-06-30 | 2.76 | -27.68 | 8.59 | |
| 2017-03-31 | 2.81 | -24.57 | 7.73 | |
| 2016-12-31 | 1.91 | -20.00 | 6.46 | |
| 2016-09-30 | 1.90 | -14.93 | 4.93 | |
| 2016-06-30 | 1.33 | -11.83 | 3.96 | |
| 2016-03-31 | 1.04 | -10.21 | 3.91 | |
| 2015-12-31 | 0.65 | -8.85 | 3.61 | |
| 2015-09-30 | 0.28 | -7.61 | 3.26 | |
| 2015-06-30 | 0.11 | -6.02 | 2.83 | |
| 2015-03-31 | -3.96 | 2.16 | ||
| 2014-12-31 | -2.54 | 1.39 | ||
| 2014-09-30 | -1.57 | 1.00 | -0.02 | |
| 2014-06-30 | -0.97 | 0.65 | 0.01 | |
| 2014-03-31 | -0.67 | 0.37 | 0.19 | |
| 2013-12-31 | -0.60 | 0.35 | 0.21 | |
| 2012-12-31 | -0.89 | 0.29 | 0.54 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Corbus Pharmaceuticals Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Corbus Pharmaceuticals Holdings's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Corbus Pharmaceuticals Holdings has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Corbus Pharmaceuticals Holdings's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Corbus Pharmaceuticals Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
- Corbus Pharmaceuticals Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Corbus Pharmaceuticals Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Corbus Pharmaceuticals Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | 42.87 | 0.00 | 55.66 |
| 2018-06-30 | 55.49 | 0.08 | 64.68 |
| 2018-03-31 | 65.54 | 0.21 | 70.96 |
| 2017-12-31 | 57.78 | 0.33 | 62.54 |
| 2017-09-30 | 31.98 | 0.00 | 36.60 |
| 2017-06-30 | 37.59 | 0.04 | 43.03 |
| 2017-03-31 | 43.59 | 0.16 | 48.93 |
| 2016-12-31 | 8.92 | 0.28 | 14.99 |
| 2016-09-30 | 13.31 | 0.01 | 18.91 |
| 2016-06-30 | 17.65 | 0.03 | 22.03 |
| 2016-03-31 | 6.40 | 0.10 | 9.69 |
| 2015-12-31 | 8.99 | 0.16 | 12.34 |
| 2015-09-30 | 11.17 | 0.00 | 13.17 |
| 2015-06-30 | 6.77 | 0.00 | 9.24 |
| 2015-03-31 | 4.69 | 0.07 | 4.97 |
| 2014-12-31 | 5.86 | 0.14 | 6.26 |
| 2014-09-30 | 7.02 | 0.08 | 7.54 |
| 2014-06-30 | 7.45 | 0.64 | 8.50 |
| 2014-03-31 | -0.79 | 0.64 | 0.16 |
| 2013-12-31 | -0.67 | 0.64 | 0.30 |
| 2012-12-31 | -0.20 | 0.63 | 0.54 |
- Corbus Pharmaceuticals Holdings has no debt.
- Corbus Pharmaceuticals Holdings currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Corbus Pharmaceuticals Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
- Corbus Pharmaceuticals Holdings has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 68.2% each year.
Financial health checks
We assess Corbus Pharmaceuticals Holdings's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Corbus Pharmaceuticals Holdings has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Corbus Pharmaceuticals Holdings
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Corbus Pharmaceuticals Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Corbus Pharmaceuticals Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 21 Stocks | 2.2% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 1986 Stocks | 2.6% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 | ||
| 2018-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Corbus Pharmaceuticals Holdings has not reported any payouts.
- Unable to verify if Corbus Pharmaceuticals Holdings's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Corbus Pharmaceuticals Holdings's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Corbus Pharmaceuticals Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Corbus Pharmaceuticals Holdings has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $3,242,269 |
| AGE | 43 |
| TENURE AS CEO | 4.8 years |
CEO Bio
Dr. Yuval Cohen, Ph.D., has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc (formerly, Morria Biopharmaceuticals Plc) from February 2013 to December 10, 2013 and served as its President since January 12, 2005 until February 2013. Dr. Cohen served as the Managing Director of Celsus Therapeutics Plc. Dr. Cohen has been the driving force behind transforming MFAID technology into the biotech start-up that is Morria. Dr. Cohen's background in both molecular biology and protein biochemistry and his interest in biotechnology enable him to understand and convey both the nature and potential of this technology. His responsibility is to develop the anti-inflammatory propriety technology platform to its full potential with various strategic partners. Dr. Cohen is committed to making Morria an unprecedented success. Dr. Cohen served as an Interim Chief Executive Officer at Celsus Therapeutics Plc. He served as a Director of Celsus Therapeutics Plc from January 12, 2005 to December 10, 2013. Dr. Cohen worked in the laboratories of Wolf Brandt (University of Cape Town) and Dietrich Averbeck (Curie Institute) on chromatin and DNA repair processes. He is also a recipient of a certificate in Business Management and Entrepreneurship from the Cape Technikon (awarded with distinction, 2002). Dr. Cohen Awards includes: Amelia Schenkman Foundation Merit bursary, Dean's List, Foundation for Research and Development bursary, Boursier du Gouvernement Français (French Ministry of Foreign Affairs), Young Scientist travel award Brussels 2001 (L-MOV), San Francisco 2000 (ASP). Dr. Cohen holds Israeli and South African nationalities and is fluent in English, French, Hebrew and Romanian. He holds BS in Microbiology and Biochemistry from University of Cape Town. Dr. Cohen holds a PhD (cum laude) from the Curie Institute and the University of Paris V in Medical Science.
CEO Compensation
- Yuval's compensation has increased whilst company is loss making.
- Yuval's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Corbus Pharmaceuticals Holdings management team in years:
- The tenure for the Corbus Pharmaceuticals Holdings management team is about average.
Management Team
Yuval Cohen
CEO & Director
$3M
43
4.8 yrs
Mark Tepper
Co-Founder
$1M
61
4.8 yrs
Sean Moran
Chief Financial Officer
$1M
60
4.8 yrs
Barbara White
Chief Medical Officer
$1M
68
4.4 yrs
Ted Jenkins
Senior Director of Investor Relations & Communications
Scott Constantine
Senior Director & Head of Clinical Operations
Board of Directors Tenure
Average tenure and age of the Corbus Pharmaceuticals Holdings board of directors in years:
- The tenure for the Corbus Pharmaceuticals Holdings board of directors is about average.
Board of Directors
Alan Holmer
Chairman
$225K
68
4.8 yrs
Yuval Cohen
CEO & Director
$3M
43
4.8 yrs
Chip Catlin
Director
$208K
70
4.4 yrs
Paris Panayiotopoulos
Director
$372K
44
1.3 yrs
George Kunos
Member of Scientific Advisory Board
0.3 yrs
David Hochman
Director
$195K
43
5.1 yrs
Charles Serhan
Member of Scientific Advisory Board
3.7 yrs
Michael Knowles
Member of Scientific Advisory Board
John Jenkins
Director
0.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 16. May 18 | Buy | Barbara White | Individual | 15. May 18 | 15. May 18 | 2,586 | $5.87 | $15,174 | ||
| 16. May 18 | Buy | Yuval Cohen | Individual | 15. May 18 | 15. May 18 | 1,725 | $5.85 | $10,091 | ||
| 15. May 18 | Buy | David Hochman | Individual | 14. May 18 | 14. May 18 | 5,000 | $5.48 | $27,375 | ||
| 15. May 18 | Buy | Sean Moran | Individual | 15. May 18 | 15. May 18 | 4,000 | $5.77 | $23,080 | ||
| 15. Mar 18 | Buy | David Hochman | Individual | 14. Mar 18 | 14. Mar 18 | 5,000 | $6.67 | $33,325 | ||
| 15. Mar 18 | Buy | Barbara White | Individual | 14. Mar 18 | 14. Mar 18 | 2,885 | $6.89 | $19,878 | ||
| 15. Mar 18 | Buy | Yuval Cohen | Individual | 14. Mar 18 | 14. Mar 18 | 1,160 | $6.89 | $7,987 | ||
| 14. Mar 18 | Buy | Sean Moran | Individual | 14. Mar 18 | 14. Mar 18 | 3,100 | $6.60 | $20,460 | ||
Management checks
We assess Corbus Pharmaceuticals Holdings's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Corbus Pharmaceuticals Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Do Directors Own Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares?
Every investor in Corbus Pharmaceuticals Holdings, Inc. … Corbus Pharmaceuticals Holdings is not a large company by global standards. … Check out our latest analysis for Corbus Pharmaceuticals Holdings
Simply Wall St - – Full articleHow Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Could Add Value To Your Portfolio
As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as
Simply Wall St - – Full articleIs Corbus Pharmaceuticals Holdings Inc's (NASDAQ:CRBP) Balance Sheet Strong Enough To Weather A Storm?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is CRBP will have to follow strict debt obligations which will reduce its financial flexibility. … Is CRBP growing fast enough to value financial flexibility over lower cost of capital.
Simply Wall St - – Full articleWhere Corbus Pharmaceuticals Holdings Inc's (NASDAQ:CRBP) Earnings Growth Stands Against Its Industry
After looking at Corbus Pharmaceuticals Holdings Inc's (NASDAQ:CRBP) latest earnings announcement (31 March 2018), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … See our latest analysis for Corbus Pharmaceuticals Holdings? … CRBP is loss-making, with the most recent trailing twelve-month earnings of -US$36.65m (from 31 March 2018), which compared to last year has become
Simply Wall St - – Full articleIs Corbus Pharmaceuticals Holdings Inc's (NASDAQ:CRBP) CEO Salary Justified?
See our latest analysis for Corbus Pharmaceuticals Holdings What has CRBP's performance been like? … In the situation of negative earnings, the company may be going through a period of reinvestment and growth, or it can be an indication of some headwind. … Normally I'd use market cap and profit as factors determining performance, however, CRBP's negative earnings reduces the usefulness of my formula.
Simply Wall St - – Full articleBrokers' Outlook On Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
CRBP has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like CRBP as a business is its low level of fixed assets on its balance sheet (2.14% of total assets). … CRBP has virtually no fixed assets, which minimizes its downside risk.
Simply Wall St - – Full articleWhen Will Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Become Profitable?
I’ve put together a brief outline of industry analyst expectations for CRBP, its year of breakeven and its implied growth rate. … View our latest analysis for Corbus Pharmaceuticals Holdings Expectation from analysts is CRBP is on the verge of breakeven. … For a more comprehensive look at CRBP, take a look at CRBP’s company page on Simply Wall St.
Simply Wall St - – Full articleCorbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP): Does -96.28% Earnings Drop In A Year Reflect The Long-Term Trend?
See our latest analysis for Corbus Pharmaceuticals Holdings Commentary On CRBP's Past Performance For the most up-to-date info, I use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Corbus Pharmaceuticals Holdings, its most recent bottom-line (trailing twelve month) is -US$29.30M, which, relative to last year’s level, has become more negative. … NasdaqGM:CRBP Income Statement Mar 1st 18 We can further examine Corbus Pharmaceuticals Holdings's loss by looking at what the industry has been experiencing over the past few years.
Simply Wall St - – Full articleAre You Backing The Right Horse With Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)?
Below, I will examine the sector growth prospects, and also determine whether Corbus Pharmaceuticals Holdings is a laggard or leader relative to its healthcare sector peers. … Moreover, the trend of below-industry growth rate is expected to continue in the future with Corbus Pharmaceuticals Holdings poised to deliver a -20.76% growth compared to the industry average growth rate of 7.24%. … Next Steps: Corbus Pharmaceuticals Holdings is a biotech industry laggard in terms of its future growth outlook.
Simply Wall St - – Full articleCorbus Pharmaceuticals Holdings Inc (CRBP): Financial Strength Analysis
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … View our latest analysis for Corbus Pharmaceuticals Holdings Does CRBP's growth rate justify its decision for financial flexibility over lower cost of capital? … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
Simply Wall St - – Full articleCompany Info
Map
Description
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.
Details
| Name: | Corbus Pharmaceuticals Holdings, Inc. |
| CRBP | |
| Exchange: | NasdaqGM |
| Founded: | 2009 |
| $442,445,844 | |
| 57,237,496 | |
| Website: | http://www.corbuspharma.com |
| Address: |
Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive, Norwood, Massachusetts, 02062, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | CRBP | New Common Shares | Nasdaq Global Market | US | USD | 27. Oct 2014 | |
| DB | 337 | New Common Shares | Deutsche Boerse AG | DE | EUR | 27. Oct 2014 | |
| LSE | 0SZI | New Common Shares | London Stock Exchange | GB | USD | 27. Oct 2014 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/01/24 00:34 |
| End of day share price update: | 2019/01/23 00:00 |
| Last estimates confirmation: | 2019/01/17 |
| Last earnings filing: | 2018/11/08 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
